NCT07281742 Amblyopia Treatment for Children Aged 8 to 12 Years
| NCT ID | NCT07281742 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Retina Foundation of the Southwest |
| Condition | Amblyopia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-01-07 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-01-07 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to assess the effect of at-home amblyopia treatment with Curesight™ for children aged 8 to 12 years. Curesight™ allows you to stream any videos on a computer screen at home but the amblyopic eye will see the entire screen clearly while part of the image will be blurred for the other eye. There is already a pivotal clinical trial showing that this treatment is effective for young children and Curesight™ has been cleared for use as an amblyopia treatment by the FDA for children as young as 4 years.
Eligibility Criteria
Inclusion Criteria: * Female and male children with amblyopia age 8-12 years inclusive * Amblyopic eye visual acuity ≤ 1.0 logMar (20/32-20/200) * Interocular difference in visual acuity of 0.3 logMAR or more * Anisometropia or strabismus corrected to \<5 pd * Wearing glasses (if needed) ≥8 weeks * No longer using standard-of-care treatments for amblyopia * Informed consent Exclusion Criteria: * Prematurity \>8 weeks * Coexisting ocular or systemic disease * Developmental delay * History of light-induced epilepsy * Eye conditions that interfere with eye tracking (nystagmus, wearing RGP contact lenses, paralysis of the extra ocular muscles or any neurological condition that restricts eye movements, ptosis that covers the pupil)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07281742 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 12 Years, studying Amblyopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07281742 currently recruiting?
Yes, NCT07281742 is actively recruiting participants. Contact the research team at ebirch@retinafoundation.org for enrollment information.
Where is the NCT07281742 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT07281742 clinical trial?
NCT07281742 is sponsored by Retina Foundation of the Southwest. The trial plans to enroll 30 participants.